Mizuho has upgraded Incyte Corp (INCY) to Outperform from Neutral, signaling a more favorable outlook for the biopharmaceutical company. This change, effective December 7, 2025, comes as Incyte's current stock price stands at $97.24.
The upgrade underscores a growing confidence in Incyte's prospects, which may stem from improved fundamentals or better-than-expected business performance. As a biotechnology firm, Incyte focuses on developing proprietary therapeutics, particularly in hematology/oncology and inflammation and autoimmunity. Notably, the company has a robust pipeline, including six marketed products and several clinical development programs.
Investors should keep in mind that analyst ratings are based on research and financial models, reflecting professional opinions that can vary widely. As of December 1, 2025, the consensus rating for Incyte is a Buy, with 9 Strong Buy, 7 Buy, 15 Hold, 1 Sell, and no Strong Sell ratings.
Looking ahead, Incyte's upcoming earnings reports are slated for April 27, 2026, with an estimated EPS of $1.71 and revenue of $1.3 billion, followed by another report on July 27, 2026, with an estimated EPS of $1.95 and revenue of $1.4 billion. With a market cap of $20.2 billion and a P/E ratio of 17.00, Incyte continues to be a key player in the biotechnology sector.
Analyst ratings can change as new information becomes available, and they should be considered alongside other factors, including company fundamentals and market conditions, when making investment decisions.